Ferroptosis-Modulating Therapies for Treatment-Resistant Malignancies

Abstract

Ferroptosis, an iron-dependent form of regulated cell death, has emerged as a compelling target in the management of treatment-resistant malignancies. Recent advances in understanding the molecular mechanisms underlying ferroptosis have spurred the development of innovative therapies aimed at overcoming resistance to conventional cancer treatments. This review synthesizes current evidence on ferroptosis modulation, evaluates its clinical relevance in refractory cancers, and discusses practical implications for oncologic practice, highlighting recent research, guideline recommendations, and future directions for integrating ferroptosis-targeted interventions in clinical oncology.

Introduction

The management of treatment-resistant malignancies remains a formidable challenge in oncology, with many patients experiencing disease progression despite multimodal therapies. Conventional chemotherapies, targeted agents, and immunotherapies often encounter resistance due to genetic, epigenetic, and microenvironmental adaptations by tumor cells. Ferroptosis, characterized by iron-dependent lipid peroxidation and distinct from apoptosis or necroptosis, has recently garnered significant attention as a novel vulnerability in refractory cancers. Modulating ferroptosis pathways offers a promising strategy to selectively induce cancer cell death, circumvent resistance mechanisms, and improve therapeutic outcomes. This review provides a comprehensive overview of ferroptosis-modulating therapies, emphasizing their mechanistic basis, translational relevance, and emerging clinical applications for treatment-resistant malignancies.

Epidemiology / Disease Burden

Treatment resistance in cancer is a major contributor to morbidity and mortality worldwide. Cancers such as glioblastoma, triple-negative breast cancer, pancreatic adenocarcinoma, and metastatic non-small cell lung cancer frequently demonstrate intrinsic or acquired resistance, resulting in poor prognosis and limited survival benefits. Globally, these refractory malignancies account for a disproportionate share of cancer-related deaths. The burden is further amplified by the high prevalence of relapse after initial response, underscoring the need for alternative therapeutic strategies that can effectively eradicate resistant tumor cell populations.

Pathophysiology

Ferroptosis is induced by the accumulation of lethal lipid peroxides in an iron-dependent manner. The process is tightly regulated by several metabolic and redox pathways, including the cystine/glutamate antiporter (system), glutathione peroxidase 4 (GPX4), and intracellular iron homeostasis. Inhibition of system impairs cystine import, depleting glutathione and reducing GPX4 activity, thus promoting lipid peroxidation. Iron overload catalyzes Fenton reactions, further amplifying oxidative damage. Unlike apoptosis, ferroptosis lacks caspase activation and is morphologically characterized by shrunken mitochondria and increased membrane density. Tumor cells with altered metabolism and high iron uptake exhibit heightened sensitivity to ferroptosis, making this pathway an attractive therapeutic target for resistant cancers.

Risk Factors

Risk factors for developing treatment resistance and potential ferroptosis sensitivity include specific oncogenic mutations (e.g., TP53, RAS), aberrant iron metabolism, overexpression of anti-apoptotic proteins, and exposure to repeated cytotoxic therapy. Tumor microenvironmental factors, such as hypoxia and nutrient deprivation, can also modulate susceptibility to ferroptosis. Furthermore, metabolic reprogramming in cancer cells manifested by increased polyunsaturated fatty acid content and altered antioxidant defenses may predispose certain malignancies to ferroptotic cell death upon therapeutic modulation.

Clinical Features

Treatment-resistant malignancies commonly present with progressive disease despite standard interventions, manifesting as locoregional recurrence, metastatic spread, or therapy-refractory lesions. Clinically, these tumors may exhibit aggressive growth, poor differentiation, and rapid clinical deterioration. While ferroptosis itself is a microscopic cellular process, its effective induction in vivo is hypothesized to manifest as tumor regression, necrosis, and potentially improved response rates in previously refractory cases.

Diagnosis

Diagnosis of treatment resistance is typically based on radiographic or clinical progression during or after standard therapy. Identification of ferroptosis susceptibility in tumors is an evolving area, with current research focusing on biomarkers such as GPX4 expression, system components (SLC7A11), and iron regulatory proteins. Advanced molecular profiling and functional assays in tumor biopsies may help stratify patients for ferroptosis-modulating therapies in the future, facilitating personalized oncologic care.

Treatment & Management

Current management of treatment-resistant malignancies involves salvage chemotherapies, re-challenge with alternative regimens, targeted therapies, immunotherapy, and palliative interventions. However, these approaches often yield limited durable responses. Ferroptosis-modulating agents, including GPX4 inhibitors (e.g., RSL3, ML210), system inhibitors (e.g., erastin, sulfasalazine), and iron chelators, have demonstrated preclinical efficacy in inducing cell death in resistant cancer models. Combination strategies integrating ferroptosis inducers with chemotherapy, radiotherapy, or immunotherapy are under investigation to enhance anti-tumor efficacy and overcome resistance mechanisms.

Recent Advances / Emerging Therapies

Recent years have witnessed a surge in translational research exploring ferroptosis as a therapeutic target. Several novel agents, such as FIN56, FINO2, and pharmacologic GPX4 inhibitors, have shown potent activity in preclinical models of resistant cancers. Nanoparticle-based delivery systems are being developed to enhance tumor-specific ferroptosis induction while minimizing off-target toxicity. Clinical trials investigating the safety and efficacy of ferroptosis-modulating compounds are ongoing, with early-phase studies reporting promising anti-tumor activity, particularly in glioblastoma, renal cell carcinoma, and hepatocellular carcinoma. Additionally, combinatorial regimens harnessing immune checkpoint inhibitors and ferroptosis inducers are being evaluated to exploit synergistic anti-cancer effects.

Guideline Recommendations

While ferroptosis-targeted therapies have not yet been incorporated into mainstream clinical guidelines, leading oncology societies emphasize the importance of enrolling patients with treatment-resistant malignancies in clinical trials assessing novel modalities, including ferroptosis modulation. Biomarker-driven patient selection and rigorous safety monitoring are strongly encouraged as these therapies advance through clinical development. Multidisciplinary collaboration between oncologists, pathologists, and pharmacologists is recommended to optimize trial design, patient selection, and outcome assessment.

Conclusion

Ferroptosis-modulating therapies represent a paradigm shift in the management of treatment-resistant malignancies, offering a mechanistically distinct approach to overcoming therapeutic inertia. Advances in molecular characterization, drug development, and translational research have paved the way for clinical implementation of ferroptosis-inducing strategies. Ongoing trials and future investigations will be pivotal in defining optimal patient selection, efficacy, and safety profiles, ultimately integrating ferroptosis-targeted interventions into the therapeutic armamentarium for refractory cancers. As the field evolves, continued interdisciplinary collaboration and evidence generation will be critical to realize the full clinical potential of ferroptosis modulation in oncology.